Literature DB >> 24023303

Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer.

Sebastian Christoph Schmid1, Tibor Schuster, Thomas Horn, Jürgen Gschwend, Uwe Treiber, Gregor Weirich.   

Abstract

BACKGROUND: Platinum-based chemotherapy is the treatment of choice for metastatic urothelial carcinoma, which is limited by primary and secondary resistance of the tumour. The Cu(2+) transporting beta polypeptide ATPase (ATP7B) is believed to play a role in this resistance. The aim of this study was to screen the ATP7B gene for mutations and loss of heterozygosity in bladder cancer and to evaluate their impact on chemotherapy resistance.
MATERIALS AND METHODS: DNA extracted from 17 patients with metastatic bladder cancer was analyzed by DNA sequencing, and microsatellite analysis.
RESULTS: We found 12 non-synonymous mutations and 20 synonymous mutations out of which 11 and 15, respectively, have not been previously described. Results were correlated with response to platinum-based chemotherapy: 65% of patients exhibited LOH of the ATP7B locus on chromosome 13q14.3, with a tendency to have a better response to chemotherapy.
CONCLUSION: Although resistance is complex, LOH at the ATP7B locus might be useful in predicting chemotherapy response and needs further evaluation.

Entities:  

Keywords:  ATP7B; LOH; bladder cancer; chemotherapy; cisplatin; urothelial carcinoma

Mesh:

Substances:

Year:  2013        PMID: 24023303

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.

Authors:  Xiang-Ping Li; Ji-Ye Yin; Ying Wang; Hui He; Xi Li; Wei-Jing Gong; Juan Chen; Chen-Yue Qian; Yi Zheng; Fang Li; Tao Yin; Zhi-Cheng Gong; Bo-Ting Zhou; Yu Zhang; Ling Xiao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2014-05-23

2.  Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.

Authors:  Xuejun Liu; Dongwei Yao; Cheng Liu; Yunjian Cao; Qiurong Yang; Zhichao Sun; Duo Liu
Journal:  Tumour Biol       Date:  2016-01-05

3.  Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study.

Authors:  Sebastian C Schmid; Leonore Thümer; Tibor Schuster; Thomas Horn; Florian Kurtz; Julia Slotta-Huspenina; Judith Seebach; Michael Straub; Tobias Maurer; Michael Autenrieth; Hubert Kübler; Margitta Retz; Ulrike Protzer; Jürgen E Gschwend; Dieter Hoffmann
Journal:  Infect Agent Cancer       Date:  2015-09-21       Impact factor: 2.965

4.  Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines.

Authors:  Margaretha A Skowron; Patrick Petzsch; Karin Hardt; Nicholas Wagner; Manfred Beier; Stefanie Stepanow; Matthias Drechsler; Harald Rieder; Karl Köhrer; Günter Niegisch; Michèle J Hoffmann; Wolfgang A Schulz
Journal:  Sci Rep       Date:  2019-10-09       Impact factor: 4.379

5.  Cuproptosis-Related Gene - SLC31A1, FDX1 and ATP7B - Polymorphisms are Associated with Risk of Lung Cancer.

Authors:  Yuhui Yun; Yun Wang; Ende Yang; Xin Jing
Journal:  Pharmgenomics Pers Med       Date:  2022-07-26

6.  Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.

Authors:  Avani Vyas; Umamaheswar Duvvuri; Kirill Kiselyov
Journal:  Biochem J       Date:  2019-12-19       Impact factor: 3.857

7.  Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Elizabeth A Guancial; Deepak Kilari; Guang-Qian Xiao; Sohaib H Abu-Farsakh; Andrea Baran; Edward M Messing; Eric S Kim
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.